Clinical data suggest that beyond-progression, the blockade of angiogenesis is associated with improved survivals in colorectal cancer. We conducted a systematic review to investigate the therapeutic effects of antiangiogenic drugs administered as later lines of treatment in patients already progressed to a previous anti-VEGF based treatment. An extensive literature search was conducted. Hazard ratios (HR) for progression (PFS) and death (OS) were extracted. An inverse-variance meta-analysis model was implemented. 6 randomized controlled trials were retrieved, including 3407 patients, treated with different antiangiogenic drugs. All of them had progressed during or after a previous line of treatment with bevacizumab. Overall, both PFS (HR=0.63, P <0.001) and OS (HR=0.81 , P < 0.001) were significantly increased with the use of antiangiogenic drug. No heterogeneity was observed despite different drugs. Protracted inhibition of the VEGF pathway is associated with a significant improvement of both PFS and OS, independently from the antiangiogenic agent used.
INTRODUCTION
Angiogenesis is a critical step in colorectal cancer growth, progression and metastasization. The process of blood vessels formation involves many different molecules and pathways. Among these, the vascular endothelial growth factors (VEGFs) driven pathway is one of the most powerful and better studied. [1] VEGFs comprises a family of multiple growth factors that act through the activation of at least three different receptors. [2] In a landmark trial, the anti-VEGF-A monoclonal antibody bevacizumab improved progression-free survival (PFS) and overall survival (OS) when added to IFL chemotherapy for the treatment of metastatic colorectal cancer patients . [3] Since then, many studies confirmed the benefit of bevacizumab when added to both first-and secondline chemotherapy. [4, 5] More recently, other drugs able to inhibit the VEGFR signaling showed efficacy, like the VEGFtrap Aflibercept, the anti VEGFR-2 Ramucirumab, and the tyrosine kinase receptor inhibitor (TKI) Regorafenib. [6] [7] [8] There are uncertainties regarding the best duration of an antiangiogenic treatment. Resistance to antiangiogenic agents can develop, mainly through the activation of other pathways like fibroblast growth factor (FGF) and platelet derived growth factor (PDGF). [9] Some authors have argued that, since resistance is established, the sudden suspension of the antiangiogenic drug can rapidly increase blood vessels formation, with more pronounced angiogenesis and faster prog ression, sug gesting possible benefits from longer treatment durations. [10] Recently, two randomized trials investigated the administration of
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bevacizumab beyond progression. [11, 12] In these studies, patients progressed after the failure of a bevacizumabbased first line chemotherapy were randomized to continuation or suspension of bevacizumab. The chemotherapy backbone was changed. They both showed that continuation of bevacizumab can effectively improve survival, even if to a small amount. In order to verify if this strategy could be generalized to all the VEGFtargeting drugs, we conducted a systematic review of all the literature available regarding the administration of antiangiogenic drugs targeting VEGF pathway after failure of a previous antiangiogenic therapy and assess if, and to what extent, a survival benefit is present.
METHODS
PubMED and EMBASE have been searched for randomized controlled trials and meta-analysis using different combinations of the following terms, with no search filter: "metastatic", "colon", "angiogenesis", "colorectal", "vascular endothelial growth factor", "beyond progression"; "Bevacizumab", "Regorafenib", "Aflibercept" and "Ramucirumab". Meta-analysis and previous systematic reviews were also searched using the same combinations with filters for "review", "meta-analysis" or "systematic review". References of the retrieved publications were screened. Abstract and poster presented at the American Society of Clinical Oncology (ASCO) annual meetings, ASCO gastrointestinal symposium, European Society of Medical Oncology (ESMO) annual meetings, and World Gastroenterology Organization (WGO) annual meetings were searched, starting from 2008, using the same combinations as above. We included prospective randomized studies investigating the administration of antiangiogenic drugs targeting the VEGF pathway, either by blocking growth factors or their receptors, irrespectively from their mechanisms of action and administered in patients progressed during or after the treatment with an anti-VEGF drug for metastatic disease. The objective of the analysis was to assess differences in PFS and in OS between patients treated with anti-VEGF therapies versus the untreated controls. PFS was defined as the time since randomization or start of the treatment to clinical evidence of progression, radiological evidence of progression or death, whichever came first. OS was defined as time since randomization or start of the treatment to death from any cause. The retrieved publications were screened by two authors at a title or abstract level. Full publications were obtained for relevant papers. Hazard ratios (HRs) for PFS and OS and their 95% confidence intervals (95% CI) were extracted from the publications. If they were not reported, they were estimated using the Parmar method. [13] The data collection form is given in appendix material. In each randomized study, only the patients previously treated with antiangiogenic agents were included. The risk of bias was evaluated by two different authors using the Cochrane Collaboration's tool. [14] Natural logarithms of the hazard ratios were used as point estimates and standard errors were calculated with the normal approximation. We used inverse variance and random effect model. Between study heterogeneity was tested with Cochran's Q test and I 2 . Sensitivity analyses were performed by repeating the analysis excluding one or more studies each time. If no heterogeneity was found, the analyses were also repeated with fixed effect model. The software used was RevMan v 5.2. PRISMA guidelines were followed to report the results. [15] 
RESULTS
Six studies including 3407 patients were included. The trial flow chart is shown in Figure 1 . All patients had been previously administered bevacizumab. Except for CORRECT and CONCUR studies, which account for 964 patients, all patients had received only one previous line of treatment. Median age ranged from 55 to 62 years. All the studies carried a low risk of bias for overall survival analysis (Table 2) . With respect to progressionfree survival, all studies were scored as low risk, with the exceptions of Bebyp and TML; both were scored as intermediate risk because of the absence of blinding. The analysis for progression free survival showed a significant difference in favor of the anti-VEGF arm with an HR of 0.63 (0.60 -0.66, P < 0.001) ( Figure 2 ). Significant heterogeneity was present, and it was mainly attributable to the CORRECT study, in which a greater benefit could be observed. Regorafenib is a TKI that is able to block multiple targets, aside from VEGFRs. We conducted a separate analysis, removing CORRECT and CONCUR, and observed the results (HR 0.71 ,0.65 -0.78, P <0.001). Heterogeneity decreased to a nonsignificant level (Cochran P value = 0.12, I 2 = 48%). The removal of one study at a time also changed the results, and very similar values of HR were obtained (data not shown). The main analysis for OS showed a significant increase in the overall survival (HR= 0.81 , 0.76 -0.87, P < 0.001) ( Figure 2 ), with no significant heterogeneity. The exclusion or regorafenib studies or the exclusion of one study at a time did not alter the results (HR = 0.83, 0.76 -0.89, P < 0.001). Small study bias and publication bias have been assessed by visual inspection of funnel plot, constructed using the log-transformed HRs for progression free survival Figure 3 ).
DISCUSSION
Angiogenesis is a key step for cancer growth and progression. Bevacizumab, an anti-VEGF-A human monoclonal antibody, was the first antiangiogenic agent approved for the treatment of colorectal cancer given its survival benefits when combined with IFL chemotherapy. [3] Subsequent trials investigated the administration of bevacizumab in combination with different regimens of chemotherapy. [4, 5] They consistently showed benefits in progression free-survival, and many of them also reported improvements in overall survival. In recent years, other antiangiogenic drugs have been developed and tested in colorectal cancer. Aflibercept is a molecular construct that is able to bind all the different isoforms of VEGF-A, as well as other members of the VEGF family. Ramucirumab is a monoclonal antibody that targets and inactivates the VEGFR-2. Both have been investigated in two large randomized controlled trials (i.e., the VELOUR and the RAISE), in combination with FOLFIRI chemotherapy in pretreated colorectal cancer patients. Both studies were positive with almost identical results. All patients enrolled in the RAISE and a significant proportion of those in the VELOUR had received prior bevacizumab. Regorafenib is a small molecule able to block multiple targets like VEGFR-1, -2 and -3, RAF, PDGFRb and kit. It was seen that regorafenib helped to improve both PFS and OS in heavily pretreated patients [8] in majority of trials; the antiangiogenic agent were suspended after progression. However, the optimal duration is unclear and there is a biological rationale to hypothesize a survival benefit from post-progression administrations. [10] The TML and the Bebyp trials investigated protracted administration of bevacizumab after progression to a first-line chemotherapy. Both trials were positive, confirming that protracted administration of bevacizumab, beyond progression, leads to survival advantage. These trials suggest that once started, antiangiogenic agents should not be discontinued. One of the main goals of this paper is to assess if this statement is limited to bevacizumab or could conversely apply to all VEGF-targeting drugs. The analysis included all the studies which investigated the administration of anti-VEGF drugs, alone or combined with chemotherapy, in patients already progressed after a previous line of treatment including antiangiogenic agents. Our results confirmed a significant improvement of both progression free and overall survival. Most notably, the magnitude of benefit was almost identical, regardless of the drug used. All the drugs included had an exclusive activity against VEGFs or VEGFR-2, with the only exception of regorafenib. However, in the CORRECT and the CONCUR studies, a very similar amount of benefit was present and if these studies were removed, the results did not change significantly. We recognize some limitations to the present analysis. The number of studies is small, and for some molecules, only one trial was available. The time between the progression and the start of treatment were different, with some studies allowing only a very short time, unlike the Bebyp in which a longer period was allowed. Even if the results appear to be very similar, the timing of second-line antiangiogenic agents may not be negligible. Moreover, the absolute benefit in survival, although statistically significant, appears to be very small. Considering the high costs and the associated toxicities, a routine use is controversial and this strategy should be evaluated case by case, also considering patient and tumor characteristics like age, comorbidities and KRAS status. Despite these limitations, the body of evidence acquired in the last decades confirms that the inhibition of VEGF signaling can effectively improve the overall survival in metastatic colorectal cancer patients, and that a prolonged administration is associated with greater benefits. Future efforts should focus on better strategy to inhibit angiogenesis as well as preventing angiogenesis resistance. Concomitant blockage of other proangiogenic factors like FGF and PDGF could improve the effectiveness of this strategy. Many agents that can target these pathways have been developed, like sorafenib and sunitinib. Unfortunately, both failed to improve prognosis in phase III randomized trials, even if sorafenib still maintains promise for pretreated KRAS mutant patients. [16] [17] [18] Other antiangiogenic molecules able to target multiple pathways are under investigation. Among these, nintedanib (BIBF 1120), a multi target TKI able to efficiently block VEGFR, FGFR and PDGFR, is one of the most promising, as it has already shown to improve survival in lung adenocarcinoma. [19] Preliminary results showed clinical activity also in colorectal cancer and results of ongoing trials are awaited in the coming years (NCT02149108, NCT02393755, NCT00904839). [20] How to cite this article: Montagnani Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).
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